BioSpace News Archive

Drug Development

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

Zambon announced today that the Company has completed enrollment in its two pivotal Phase 3 studies.

May 1, 2023
·
5 min read
Genetown

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology today announced that the Company will participate in the following upcoming investor conferences.

May 1, 2023
·
1 min read
Business

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Immatics N.V. (NASDAQ: IMTX, “Immatics”) today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration.

May 1, 2023
·
4 min read
Pharm Country

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

Axsome Therapeutics, Inc. is joining Mental Health America (MHA) and the State of New York to raise awareness of mental health during May is Mental Health Month.

May 1, 2023
·
7 min read
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism.

May 1, 2023
·
6 min read
Deals

ACELYRIN, INC. Announces Launch of IPO Roadshow

ACELYRIN, INC. today announced it has launched a roadshow for an initial public offering (IPO) of 20,600,000 shares of its common stock.

May 1, 2023
·
2 min read
Pharm Country

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl ® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS).

May 1, 2023
·
13 min read
Biotech Beach

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.

May 1, 2023
·
8 min read
Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Bausch + Lomb Corporation, today released its annual Environmental, Social and Governance (ESG) Report, highlighting the Company’s ongoing commitment to implement sustainable business practices and initiatives that support its stakeholders’ well-being.

May 1, 2023
·
4 min read
Genetown

AlloVir to Present at the BofA Securities 2023 Health Care Conference

AlloVir, Inc. announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, NV on Tuesday, May 9, 2023, at 8:40 a.m. PDT.

May 1, 2023
·
1 min read